- 4671
- 2026/10/09
- 時価
- 285億円
- PER 予
- 13.18倍
- 2009年以降
- 4.76-92.25倍
（2009-2026年） - PBR
- 1.05倍
- 2009年以降
- 0.54-1.3倍
（2009-2026年） - 配当 予
- 4.79%
- ROE 予
- 7.98%
- ROA 予
- 5.44%
- 資料
- Link
- CSV,JSON
ファルコ HD（4671）のセグメントごとの売上高・利益等
セグメント通期
- 【有報】
- セグメント情報等、連結財務諸表
| 科目 | 年度 | 調剤薬局事業 | 臨床検査事業 | ICT事業 |
|---|---|---|---|---|
| 売上高 | 2013/03 | 177億 | 292億 | - |
| 2014/03 | 185億 +4.6% | 289億 -1% | - | |
| 2015/03 | 179億 -3.6% | 287億 -0.8% | - | |
| 2016/03 | 201億 +12.4% | 286億 -0.3% | - | |
| 2017/03 | 181億 -9.8% | 278億 -2.8% | - | |
| 2018/03 | 182億 +0.4% | 278億 -0.3% | - | |
| 2019/03 | 170億 -6.7% | 272億 -2.1% | - | |
| 2020/03 | 170億 +0.4% | 261億 -3.8% | - | |
| 2021/03 | 164億 -3.7% | 272億 +4% | - | |
| 2022/03 | 164億 -0.4% | 337億 +23.8% | - | |
| 2023/03 | 160億 -2.3% | 301億 -10.4% | 7.94億 | |
| 2024/03 | 160億 +0.1% | 260億 -13.9% | 10.7億 +34.6% | |
| 2025/03 | 155億 -3.3% | 264億 +1.7% | 14.5億 +35.8% | |
| 2026/03 | 152億 -1.7% | 267億 +1% | 17.2億 +18.5% | |
| 科目 | 年度 | 調剤薬局事業 | 臨床検査事業 | ICT事業 |
| 営業利益 | 2013/03 | 10.3億 | 10.8億 | - |
| 2014/03 | 11.6億 +13% | 1.21億 -88.8% | - | |
| 2015/03 | 13.6億 +17.3% | 4.22億 +248.8% | - | |
| 2016/03 | 16.7億 +22.6% | 7億 +65.9% | - | |
| 2017/03 | 12.7億 -24.1% | 11.7億 +67% | - | |
| 2018/03 | 14億 +10.8% | 9.8億 -16.2% | - | |
| 2019/03 | 8.81億 -37.2% | 6.34億 -35.3% | - | |
| 2020/03 | 10.4億 +18.4% | 0.41億 -93.5% | - | |
| 2021/03 | 9.68億 -7.2% | 19.7億 +999.99% | - | |
| 2022/03 | 10.1億 +3.8% | 48.9億 +148% | - | |
| 2023/03 | 8.92億 -11.2% | 28.9億 -41% | -141百万 | |
| 2024/03 | 9.6億 +7.6% | 15.1億 -47.9% | 142百万 | |
| 2025/03 | 8.16億 -15% | 15.9億 +5.9% | 353百万 +148.6% | |
| 2026/03 | 6.74億 -17.4% | 18.2億 +13.9% | 458百万 +29.7% | |
| 科目 | 年度 | 調剤薬局事業 | 臨床検査事業 | ICT事業 |
| 営業利益率 | 2013/03 | 5.8% | 3.7% | - |
| 2014/03 | 6.3% +0.5% | 0.4% -3.3% | - | |
| 2015/03 | 7.6% +1.3% | 1.5% +1.1% | - | |
| 2016/03 | 8.3% +0.7% | 2.4% +0.9% | - | |
| 2017/03 | 7% -1.3% | 4.2% +1.8% | - | |
| 2018/03 | 7.7% +0.7% | 3.5% -0.7% | - | |
| 2019/03 | 5.2% -2.5% | 2.3% -1.2% | - | |
| 2020/03 | 6.1% +0.9% | 0.2% -2.1% | - | |
| 2021/03 | 5.9% -0.2% | 7.3% +7.1% | - | |
| 2022/03 | 6.1% +0.2% | 14.5% +7.2% | - | |
| 2023/03 | 5.6% -0.5% | 9.6% -4.9% | -17.8% | |
| 2024/03 | 6% +0.4% | 5.8% -3.8% | 13.3% | |
| 2025/03 | 5.3% -0.7% | 6% +0.2% | 24.3% +11% | |
| 2026/03 | 4.4% -0.9% | 6.8% +0.8% | 26.6% +2.3% | |
| 科目 | 年度 | 調剤薬局事業 | 臨床検査事業 | ICT事業 |
| 設備投資額 | 2013/03 | - | - | - |
| 2014/03 | - | - | - | |
| 2015/03 | - | - | - | |
| 2016/03 | - | - | - | |
| 2017/03 | - | - | - | |
| 2018/03 | - | - | - | |
| 2019/03 | 184百万 | 5.7億 | - | |
| 2020/03 | 157百万 -14.7% | 16.2億 +184.9% | - | |
| 2021/03 | 30百万 -80.9% | 3.1億 -80.9% | - | |
| 2022/03 | 201百万 +570% | 5.8億 +87.1% | - | |
| 2023/03 | 93百万 -53.7% | 3.81億 -34.3% | - | |
| 2024/03 | 128百万 +37.6% | 5.01億 +31.5% | 88百万 | |
| 2025/03 | 142百万 +10.9% | 6.23億 +24.4% | 133百万 +51.1% | |
| 2026/03 | 157百万 +10.6% | 7.12億 +14.3% | 160百万 +20.3% | |
| 科目 | 年度 | 調剤薬局事業 | 臨床検査事業 | ICT事業 |
| 固定資産増加額 | 2013/03 | 287百万 | 6.31億 | - |
| 2014/03 | 196百万 -31.7% | 7.62億 +20.8% | - | |
| 2015/03 | 186百万 -5.1% | 5.06億 -33.6% | - | |
| 2016/03 | 155百万 -16.7% | 3.06億 -39.5% | - | |
| 2017/03 | 87百万 -43.9% | 4.84億 +58.2% | - | |
| 2018/03 | 127百万 +46% | 6.86億 +41.7% | - | |
| 2019/03 | 187百万 +47.2% | 5.77億 -15.9% | - | |
| 2020/03 | 157百万 -16% | 16.2億 +181.5% | - | |
| 2021/03 | 30百万 -80.9% | 3.1億 -80.9% | - | |
| 2022/03 | 204百万 +580% | 5.8億 +87.1% | - | |
| 2023/03 | 97百万 -52.5% | 3.41億 -41.2% | 40百万 | |
| 2024/03 | 167百万 +72.2% | 5.58億 +63.6% | 88百万 +120% | |
| 2025/03 | 143百万 -14.4% | 6.24億 +11.8% | 133百万 +51.1% | |
| 2026/03 | 185百万 +29.4% | 7.28億 +16.7% | 165百万 +24.1% | |
| 科目 | 年度 | 調剤薬局事業 | 臨床検査事業 | ICT事業 |
| 従業員数 | 2013/03 | - | - | - |
| 2014/03 | - | - | - | |
| 2015/03 | - | - | - | |
| 2016/03 | - | - | - | |
| 2017/03 | - | - | - | |
| 2018/03 | - | - | - | |
| 2019/03 | 408 | 895 | - | |
| 2020/03 | 399 -2.2% | 811 -9.4% | - | |
| 2021/03 | 394 -1.3% | 782 -3.6% | - | |
| 2022/03 | 393 -0.3% | 762 -2.6% | - | |
| 2023/03 | 402 +2.3% | 736 -3.4% | - | |
| 2024/03 | 386 -4% | 658 -10.6% | 48 | |
| 2025/03 | 373 -3.4% | 608 -7.6% | 58 +20.8% | |
| 2026/03 | 373 ±0% | 570 -6.3% | 71 +22.4% | |
| 科目 | 年度 | 調剤薬局事業 | 臨床検査事業 | ICT事業 |
| 平均臨時雇用人員 | 2013/03 | - | - | - |
| 2014/03 | - | - | - | |
| 2015/03 | - | - | - | |
| 2016/03 | - | - | - | |
| 2017/03 | - | - | - | |
| 2018/03 | - | - | - | |
| 2019/03 | 185 | 1,178 | - | |
| 2020/03 | 183 -1.1% | 1,084 -8% | - | |
| 2021/03 | 185 +1.1% | 1,124 +3.7% | - | |
| 2022/03 | 177 -4.3% | 1,215 +8.1% | - | |
| 2023/03 | 174 -1.7% | 1,187 -2.3% | - | |
| 2024/03 | 168 -3.4% | 1,094 -7.8% | 5 | |
| 2025/03 | 168 ±0% | 1,062 -2.9% | 4 -20% | |
| 2026/03 | 158 -6% | 1,079 +1.6% | 4 ±0% | |
| 科目 | 年度 | 調剤薬局事業 | 臨床検査事業 | ICT事業 |
| 資産 | 2013/03 | 75.5億 | 137億 | - |
| 2014/03 | 74億 -2.1% | 106億 -22.9% | - | |
| 2015/03 | 79.4億 +7.4% | 101億 -4.9% | - | |
| 2016/03 | 87.6億 +10.3% | 95.4億 -5.2% | - | |
| 2017/03 | 57.7億 -34.1% | 92億 -3.6% | - | |
| 2018/03 | 56.2億 -2.6% | 106億 +14.9% | - | |
| 2019/03 | 56.3億 +0.1% | 90.6億 -14.3% | - | |
| 2020/03 | 51.7億 -8.2% | 103億 +13.3% | - | |
| 2021/03 | 51.5億 -0.3% | 110億 +7.6% | - | |
| 2022/03 | 56.2億 +9% | 131億 +18.8% | - | |
| 2023/03 | 53.1億 -5.5% | 103億 -21.1% | 707百万 | |
| 2024/03 | 54億 +1.7% | 95.1億 -8.1% | 828百万 +17.1% | |
| 2025/03 | 50.2億 -7% | 94.6億 -0.5% | 842百万 +1.7% | |
| 2026/03 | 50.4億 +0.3% | 93億 -1.7% | 931百万 +10.6% | |
| 科目 | 年度 | 調剤薬局事業 | 臨床検査事業 | ICT事業 |
| 減損損失 | 2013/03 | 91百万 | - | - |
| 2014/03 | 23百万 -74.7% | 3百万 | - | |
| 2015/03 | 13百万 -43.5% | 5百万 +66.7% | - | |
| 2016/03 | 0 | - | - | |
| 2017/03 | 39百万 | 6百万 | - | |
| 2018/03 | 4百万 -89.7% | - | - | |
| 2019/03 | 48百万 +999.99% | - | - | |
| 2020/03 | 99百万 +106.3% | 6百万 | - | |
| 2021/03 | 64百万 -35.4% | 4百万 -33.3% | - | |
| 2022/03 | 35百万 -45.3% | 0 | - | |
| 2023/03 | 59百万 +68.6% | - | - | |
| 2024/03 | 105百万 +78% | - | - | |
| 2025/03 | 99百万 -5.7% | - | 18百万 | |
| 2026/03 | 30百万 -69.7% | - | - | |
| 科目 | 年度 | 調剤薬局事業 | 臨床検査事業 | ICT事業 |
| のれん | 2013/03 | 108百万 | 145百万 | - |
| 2014/03 | 22百万 -79.6% | 95百万 -34.5% | - | |
| 2015/03 | 94百万 +327.3% | 45百万 -52.6% | - | |
| 2016/03 | 76百万 -19.1% | - | - | |
| 2017/03 | 59百万 -22.4% | - | - | |
| 2018/03 | 42百万 -28.8% | - | - | |
| 2019/03 | 24百万 -42.9% | 66百万 | - | |
| 2020/03 | 8百万 -66.7% | 52百万 -21.2% | - | |
| 2021/03 | 6百万 -25% | 38百万 -26.9% | - | |
| 2022/03 | 4百万 -33.3% | 24百万 -36.8% | - | |
| 2023/03 | 2百万 -50% | 10百万 -58.3% | 10百万 | |
| 2024/03 | - | - | 23百万 +130% | |
| 2025/03 | - | - | - | |
| 2026/03 | - | - | - | |
| 科目 | 年度 | 調剤薬局事業 | 臨床検査事業 | ICT事業 |
| のれん償却額 | 2013/03 | 12百万 | 49百万 | - |
| 2014/03 | 9百万 -25% | 49百万 ±0% | - | |
| 2015/03 | 3百万 -66.7% | 49百万 ±0% | - | |
| 2016/03 | 17百万 +466.7% | 45百万 -8.2% | - | |
| 2017/03 | 17百万 ±0% | - | - | |
| 2018/03 | 17百万 ±0% | - | - | |
| 2019/03 | 17百万 ±0% | 3百万 | - | |
| 2020/03 | 16百万 -5.9% | 14百万 +366.7% | - | |
| 2021/03 | 2百万 -87.5% | 14百万 ±0% | - | |
| 2022/03 | 2百万 ±0% | 14百万 ±0% | - | |
| 2023/03 | 2百万 ±0% | 14百万 ±0% | 14百万 | |
| 2024/03 | 2百万 ±0% | - | 12百万 -14.3% | |
| 2025/03 | - | - | 5百万 -58.3% | |
| 2026/03 | - | - | - |
セグメント四半期
| 科目 | 年度 | 1Q | 2Q | 3Q | 4Q | 通期 |
|---|---|---|---|---|---|---|
| 調剤薬局事業 | ||||||
| 売上高 1Q2Q 3Q | 2014/03 | 46.2億 | 46.4億 | 49億 | 43.9億 | 185億 |
| 2015/03 | 43.3億 -6.2% | 43.8億 -5.5% | 45.9億 -6.3% | 45.8億 +4.3% | 179億 -3.6% | |
| 2016/03 | 47.9億 +10.7% | 48億 +9.5% | 52.5億 +14.4% | 52.5億 +14.7% | 201億 +12.4% | |
| 2017/03 | 45.6億 -4.9% | 45.5億 -5.2% | 45.6億 -13.2% | 44.6億 -15.1% | 181億 -9.8% | |
| 2018/03 | 45.3億 -0.6% | 44.7億 -1.6% | 46.6億 +2.2% | 45.3億 +1.6% | 182億 +0.4% | |
| 2019/03 | 41.9億 -7.5% | 41.2億 -7.9% | 44.1億 -5.3% | 42.6億 -5.9% | 170億 -6.7% | |
| 2020/03 | 42.7億 +1.8% | 42.3億 +2.7% | 43.4億 -1.6% | 42.1億 -1.3% | 170億 +0.4% | |
| 2021/03 | 40.2億 -5.9% | 40.7億 -3.9% | 42.3億 -2.6% | 41億 -2.5% | 164億 -3.7% | |
| 2022/03 | 39.9億 -0.6% | 40.6億 -0.1% | 42.2億 -0.3% | 40.8億 -0.5% | 164億 -0.4% | |
| 2023/03 | 38.9億 -2.5% | 40.2億 -1% | 40.7億 -3.4% | 39.9億 -2.4% | 160億 -2.3% | |
| 2024/03 | 38.9億 -0.1% | 40.2億 -0.1% | 41億 +0.7% | 39.8億 -0.1% | 160億 +0.1% | |
| 営業利益 1Q2Q 3Q | 2014/03 | 2.76億 | 2.91億 | 3.04億 | 2.88億 | 11.6億 |
| 2015/03 | 1.71億 -38% | 4.62億 +58.8% | 3.72億 +22.4% | 3.55億 +23.3% | 13.6億 +17.3% | |
| 2016/03 | 3.27億 +91.2% | 4.01億 -13.2% | 4.48億 +20.4% | 4.92億 +38.6% | 16.7億 +22.6% | |
| 2017/03 | 1.3億 -60.2% | 3.96億 -1.2% | 3.47億 -22.5% | 3.93億 -20.1% | 12.7億 -24.1% | |
| 2018/03 | 3億 +130.8% | 3.57億 -9.8% | 3.45億 -0.6% | 4.01億 +2% | 14億 +10.8% | |
| 2019/03 | 0.19億 -93.7% | 2.77億 -22.4% | 2.45億 -29% | 3.4億 -15.2% | 8.81億 -37.2% | |
| 2020/03 | 2.31億 +999.99% | 2.74億 -1.1% | 0.73億 -70.2% | 4.65億 +36.8% | 10.4億 +18.4% | |
| 2021/03 | 0.49億 -78.8% | 3.79億 +38.3% | 2.47億 +238.4% | 2.93億 -37% | 9.68億 -7.2% | |
| 2022/03 | 1.02億 +108.2% | 4.21億 +11.1% | 2.47億 ±0% | 2.35億 -19.8% | 10.1億 +3.8% | |
| 2023/03 | 0.06億 -94.1% | 3.14億 -25.4% | 2.7億 +9.3% | 3.02億 +28.5% | 8.92億 -11.2% | |
| 2024/03 | 0.55億 +816.7% | 3.3億 +5.1% | 2.76億 +2.2% | 2.99億 -1% | 9.6億 +7.6% | |
| 営業利益率 | 2014/03 | 6% | 6.3% | 6.2% | 6.6% | 6.3% |
| 2015/03 | 3.9% -2.1% | 10.5% +4.2% | 8.1% +1.9% | 7.8% +1.2% | 7.6% +1.3% | |
| 2016/03 | 6.8% +2.9% | 8.4% -2.1% | 8.5% +0.4% | 9.4% +1.6% | 8.3% +0.7% | |
| 2017/03 | 2.9% -3.9% | 8.7% +0.3% | 7.6% -0.9% | 8.8% -0.6% | 7% -1.3% | |
| 2018/03 | 6.6% +3.7% | 8% -0.7% | 7.4% -0.2% | 8.8% ±0% | 7.7% +0.7% | |
| 2019/03 | 0.5% -6.1% | 6.7% -1.3% | 5.6% -1.8% | 8% -0.8% | 5.2% -2.5% | |
| 2020/03 | 5.4% +4.9% | 6.5% -0.2% | 1.7% -3.9% | 11% +3% | 6.1% +0.9% | |
| 2021/03 | 1.2% -4.2% | 9.3% +2.8% | 5.8% +4.1% | 7.1% -3.9% | 5.9% -0.2% | |
| 2022/03 | 2.6% +1.4% | 10.4% +1.1% | 5.9% +0.1% | 5.8% -1.3% | 6.1% +0.2% | |
| 2023/03 | 0.2% -2.4% | 7.8% -2.6% | 6.6% +0.7% | 7.6% +1.8% | 5.6% -0.5% | |
| 2024/03 | 1.4% +1.2% | 8.2% +0.4% | 6.7% +0.1% | 7.5% -0.1% | 6% +0.4% | |
| 科目 | 年度 | 1Q | 2Q | 3Q | 4Q | 通期 |
| 臨床検査事業 | ||||||
| 売上高 1Q2Q 3Q | 2014/03 | 75.9億 | 71.8億 | 72.2億 | 69.6億 | 289億 |
| 2015/03 | 73.7億 -2.9% | 71.1億 -1% | 71.3億 -1.2% | 71.1億 +2.1% | 287億 -0.8% | |
| 2016/03 | 73.8億 +0.1% | 70.4億 -1% | 71.9億 +0.9% | 70.3億 -1.1% | 286億 -0.3% | |
| 2017/03 | 72.1億 -2.3% | 69.2億 -1.6% | 69.5億 -3.4% | 67.6億 -3.7% | 278億 -2.8% | |
| 2018/03 | 70.7億 -1.9% | 68.6億 -1% | 69.9億 +0.7% | 68.5億 +1.2% | 278億 -0.3% | |
| 2019/03 | 71.2億 +0.7% | 66.5億 -3.1% | 70.5億 +0.8% | 63.6億 -7.2% | 272億 -2.1% | |
| 2020/03 | 66.3億 -6.9% | 67.9億 +2.1% | 65.1億 -7.6% | 62.1億 -2.3% | 261億 -3.8% | |
| 2021/03 | 57.3億 -13.6% | 65.7億 -3.1% | 73.3億 +12.6% | 75.6億 +21.8% | 272億 +4% | |
| 2022/03 | 80.3億 +40.1% | 86.1億 +31% | 75.3億 +2.7% | 94.8億 +25.5% | 337億 +23.8% | |
| 2023/03 | 75.7億 -5.7% | 83.7億 -2.8% | 74.8億 -0.7% | 67.2億 -29.1% | 301億 -10.4% | |
| 2024/03 | 65.6億 -13.4% | 64.1億 -23.4% | 66.2億 -11.4% | 63.6億 -5.5% | 260億 -13.9% | |
| 営業利益 1Q2Q 3Q | 2014/03 | 3.45億 | 0.86億 | 0.17億 | -3.27億 | 1.21億 |
| 2015/03 | 1.73億 -49.9% | 0.93億 +8.1% | 1.1億 +547.1% | 0.46億 | 4.22億 +248.8% | |
| 2016/03 | 2.5億 +44.5% | 0.3億 -67.7% | 2.75億 +150% | 1.45億 +215.2% | 7億 +65.9% | |
| 2017/03 | 3.55億 +42% | 3.01億 +903.3% | 3.18億 +15.6% | 1.95億 +34.5% | 11.7億 +67% | |
| 2018/03 | 3.13億 -11.8% | 3.08億 +2.3% | 1.71億 -46.2% | 1.88億 -3.6% | 9.8億 -16.2% | |
| 2019/03 | 3.81億 +21.7% | 1.35億 -56.2% | 3.22億 +88.3% | -2.04億 赤字 | 6.34億 -35.3% | |
| 2020/03 | 0.99億 -74% | 1.97億 +45.9% | -0.42億 赤字 | -2.13億 赤字 | 0.41億 -93.5% | |
| 2021/03 | -1.19億 赤字 | 4.96億 +151.8% | 7.03億 | 8.93億 | 19.7億 +999.99% | |
| 2022/03 | 12.6億 | 15.3億 +208.7% | 5.13億 -27% | 15.9億 +78.2% | 48.9億 +148% | |
| 2023/03 | 8.55億 -32.1% | 8.78億 -42.7% | 7.19億 +40.2% | 4.34億 -72.7% | 28.9億 -41% | |
| 2024/03 | 3.48億 -59.3% | 3.41億 -61.2% | 3.99億 -44.5% | 4.17億 -3.9% | 15.1億 -47.9% | |
| 営業利益率 | 2014/03 | 4.5% | 1.2% | 0.2% | -4.7% | 0.4% |
| 2015/03 | 2.3% -2.2% | 1.3% +0.1% | 1.5% +1.3% | 0.6% | 1.5% +1.1% | |
| 2016/03 | 3.4% +1.1% | 0.4% -0.9% | 3.8% +2.3% | 2.1% +1.5% | 2.4% +0.9% | |
| 2017/03 | 4.9% +1.5% | 4.3% +3.9% | 4.6% +0.8% | 2.9% +0.8% | 4.2% +1.8% | |
| 2018/03 | 4.4% -0.5% | 4.5% +0.2% | 2.4% -2.2% | 2.7% -0.2% | 3.5% -0.7% | |
| 2019/03 | 5.3% +0.9% | 2% -2.5% | 4.6% +2.2% | -3.2% 赤字 | 2.3% -1.2% | |
| 2020/03 | 1.5% -3.8% | 2.9% +0.9% | -0.6% 赤字 | -3.4% 赤字 | 0.2% -2.1% | |
| 2021/03 | -2.1% 赤字 | 7.5% +4.6% | 9.6% | 11.8% | 7.3% +7.1% | |
| 2022/03 | 15.7% | 17.8% +10.3% | 6.8% -2.8% | 16.8% +5% | 14.5% +7.2% | |
| 2023/03 | 11.3% -4.4% | 10.5% -7.3% | 9.6% +2.8% | 6.5% -10.3% | 9.6% -4.9% | |
| 2024/03 | 5.3% -6% | 5.3% -5.2% | 6% -3.6% | 6.6% +0.1% | 5.8% -3.8% | |
| 科目 | 年度 | 1Q | 2Q | 3Q | 4Q | 通期 |
| ICT事業 | ||||||
| 売上高 1Q2Q 3Q | 2023/03 | 1.02億 | 1.91億 | 1.76億 | 3.25億 | 7.94億 |
| 2024/03 | 1.9億 +86.3% | 2.59億 +35.6% | 2.67億 +51.7% | 3.53億 +8.6% | 10.7億 +34.6% | |
| 営業利益 1Q2Q 3Q | 2023/03 | -73百万 | -26百万 | -71百万 | 29百万 | -141百万 |
| 2024/03 | -8百万 赤字 | 54百万 | 25百万 | 71百万 +144.8% | 142百万 | |
| 営業利益率 | 2023/03 | -71.6% | -13.6% | -40.3% | 8.9% | -17.8% |
| 2024/03 | -4.2% 赤字 | 20.8% | 9.4% | 20.1% +11.2% | 13.3% | |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
